Initiation: Kinarus making p38 MAP kinase inhibition viable
That is, until the founders of Kinarus discovered and patented the use of a p38 MAP kinase in combination with another, already-approved, generic drug that does make the mechanism viable. KIN001 is that drug, with pamapimod licensed from Roche Holding AG who retain opt-in rights.Kinarus' licensing strategy has resulted in them becoming a mid-stage clinical development company without the cost and time implications of drug discovery and toxicology programs. This is because Roche (Kinarus’s licensor) conducted those, and other studies.
We initiate coverage today. The largest component of our valuation is a risk-adjusted NPV analysis of Kinarus’ product KIN001 in wAMD, but it also includes contributions from its potential use in COVID-19 and, further out in the timeline, idiopathic pulmonary fibrosis.
Our fair value of Kinarus AG is CHF107.6m, or CHF0.10 per share
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.